It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
X-linked lymphoproliferative disease (XLP) is either caused by loss of the SLAM-associated protein (SAP; XLP-1) or the X-linked inhibitor of apoptosis (XIAP; XLP-2). In both instances, infection with the oncogenic human Epstein Barr virus (EBV) leads to pathology, but EBV-associated lymphomas only emerge in XLP-1 patients. Therefore, we investigated the role of XIAP during B cell transformation by EBV. Using humanized mice, IAP inhibition in EBV-infected mice led to a loss of B cells and a tendency to lower viral titers and lymphomagenesis. Loss of memory B cells was also observed in four newly described patients with XIAP deficiency. EBV was able to transform their B cells into lymphoblastoid cell lines (LCLs) with similar growth characteristics to patient mothers’ LCLs in vitro and in vivo. Gene expression analysis revealed modest elevated lytic EBV gene transcription as well as the expression of the tumor suppressor cell adhesion molecule 1 (CADM1). CADM1 expression on EBV-infected B cells might therefore inhibit EBV-associated lymphomagenesis in patients and result in the absence of EBV-associated malignancies in XLP-2 patients.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 University of Zürich, Viral Immunobiology, Institute of Experimental Immunology, Zürich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
2 Virus Genomics, Heinrich Pette Institute, Hamburg, Germany (GRID:grid.418481.0) (ISNI:0000 0001 0665 103X)
3 University Children’s Hospital Zurich, Division of Immunology, Zurich, Switzerland (GRID:grid.412341.1) (ISNI:0000 0001 0726 4330)
4 University of Cincinnati, Department of Pediatrics, Cincinnati, USA (GRID:grid.24827.3b) (ISNI:0000 0001 2179 9593)
5 University of Zürich, Cell Death and Regulation of Inflammation, Institute of Experimental Immunology, Zürich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)